Post by Vector BioMed, Inc.

The future of CAR-T access depends on making manufacturing more affordable, practical, scalable, and closer to patients.    LENTIVERSE™ LaunchSuite brings together CGMP lentiviral vector, reagents, documentation, and a cell manufacturing workflow designed to support affordable point-of-care CAR-T programs.    Because expanding access requires more than innovation at the bench.   It requires manufacturing models built for real-world deployment.    Learn more: https://lnkd.in/gUi72nHP